TR200401186T4 - Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları. - Google Patents
Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.Info
- Publication number
- TR200401186T4 TR200401186T4 TR2004/01186T TR200401186T TR200401186T4 TR 200401186 T4 TR200401186 T4 TR 200401186T4 TR 2004/01186 T TR2004/01186 T TR 2004/01186T TR 200401186 T TR200401186 T TR 200401186T TR 200401186 T4 TR200401186 T4 TR 200401186T4
- Authority
- TR
- Turkey
- Prior art keywords
- virus
- artificial chromosome
- directing
- formation
- nucleic acid
- Prior art date
Links
- 241001493065 dsRNA viruses Species 0.000 title abstract 3
- 210000004507 artificial chromosome Anatomy 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 150000007523 nucleic acids Chemical group 0.000 title 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 abstract 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 101710172711 Structural protein Proteins 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A61K39/225—Porcine transmissible gastroenteritis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20041—Use of virus, viral particle or viral elements as a vector
- C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
- C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Mevcut bulus, bir DNA hazirlanmasina yönelik olup asagidaki asamalari içeren metotlarla ilgilidir; (a) genomik RNA'nin (gRNA) veya bir RNA virüsünün tam uzunlukta bir transkripsiyonu içeren bir DNA'nin; veya (b) bir gRNA'nin veya bir RNA virüsünün, RNA'ya bagli bir RNA polimerazini ve en az bir yapisal veya yapisal olamyan proteini kodlayan bir veya birkaç parçacigini içeren bir DNA'nin veya (c) (a) veya (b)'deki sekanslara en az % 60 benzerlik gösteren bir DNA'nin, bakteriyel suni bir kromozom (BAC) içerisine klonlanmasi.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009902673A ES2170622B1 (es) | 1999-12-03 | 1999-12-03 | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200401186T4 true TR200401186T4 (tr) | 2004-07-21 |
Family
ID=8310818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2004/01186T TR200401186T4 (tr) | 1999-12-03 | 2000-11-30 | Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları. |
Country Status (27)
Country | Link |
---|---|
US (4) | US7445928B2 (tr) |
EP (2) | EP1437400A3 (tr) |
JP (1) | JP4637432B2 (tr) |
KR (1) | KR100755814B1 (tr) |
CN (3) | CN100402643C (tr) |
AR (1) | AR027893A1 (tr) |
AT (1) | ATE267246T1 (tr) |
AU (2) | AU785081B2 (tr) |
BR (1) | BR0016145A (tr) |
CA (1) | CA2393325A1 (tr) |
CZ (1) | CZ302785B6 (tr) |
DE (1) | DE60010921T3 (tr) |
DK (1) | DK1234024T4 (tr) |
ES (2) | ES2170622B1 (tr) |
HU (1) | HU228205B1 (tr) |
IL (2) | IL149859A0 (tr) |
MX (1) | MXPA02005525A (tr) |
NO (1) | NO331812B1 (tr) |
NZ (1) | NZ518990A (tr) |
PL (1) | PL206816B1 (tr) |
PT (1) | PT1234024E (tr) |
RS (1) | RS50372B (tr) |
SI (1) | SI1234024T2 (tr) |
SK (1) | SK7612002A3 (tr) |
TR (1) | TR200401186T4 (tr) |
WO (1) | WO2001039797A2 (tr) |
ZA (1) | ZA200203560B (tr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2170622B1 (es) | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
US7556957B2 (en) | 2001-05-17 | 2009-07-07 | Stichting Voor De Technische Wetenschappen | Coronavirus-like particles comprising functionally deleted genomes |
BR0209837A (pt) * | 2001-05-17 | 2004-12-14 | Univ Utrecht | Partìcula semelhante a vìrus isolada ou recombimante capaz de replicação, composição, e, método para inibir ou bloquear uma infecção com um coronavìrus ou partìcula semelhante a coronavìrus |
US7906311B2 (en) | 2002-03-20 | 2011-03-15 | Merial Limited | Cotton rat lung cells for virus culture |
US7371837B2 (en) * | 2004-07-21 | 2008-05-13 | The University Of Hong Kong | Human virus causing respiratory tract infection and uses thereof |
EP1619246A1 (en) * | 2004-07-23 | 2006-01-25 | Université de la Méditerranée, Aix-Marseille II | RNA dependent RNA polymerases from coronavirus and their use in molecular biology and drug screening |
CA2591532A1 (en) | 2004-09-03 | 2006-03-09 | Consejo Superior De Investigaciones Cientificas | Nucleic acid sequences encoding proteins capable of associating into a virus-like particle |
EP1632247A1 (en) * | 2004-09-03 | 2006-03-08 | Consejo Superior De Investigaciones Cientificas | Nucleic acid sequences encoding FMDV proteins capable of associating into a virus-like particle |
AU2005299413A1 (en) | 2004-10-22 | 2006-05-04 | Revivicor, Inc. | Ungulates with genetically modified immune systems |
EP1792996A1 (en) * | 2005-12-01 | 2007-06-06 | Consejo Superior de Investigaciones Cientificas | Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV) |
JP2007312649A (ja) * | 2006-05-24 | 2007-12-06 | Japan Health Science Foundation | 再構築された感染性レトロウイルスゲノムクローンdna及びそれを含む微生物ならびにそれらの製造方法 |
DK2348827T3 (en) | 2008-10-27 | 2015-07-20 | Revivicor Inc | IMMUNICIPLY COMPROMATED PETS |
FR2947839A1 (fr) * | 2009-07-09 | 2011-01-14 | Centre Nat Rech Scient | Nouveaux agents antibacteriens |
EP2681232A1 (en) | 2011-03-02 | 2014-01-08 | Intervet International B.V. | Infectious bronchitis virus (ibv) spike protein as subunit vaccine |
GB201307528D0 (en) | 2013-04-26 | 2013-06-12 | Univ Leuven Kath | Bacterial artificial chromosomes |
CA2948181A1 (en) * | 2014-05-16 | 2015-11-19 | Yale University | Virus like vesicles (vlvs) based vaccines to prevent or treat chronic hepatitis b virus (hbv) infection |
EP3143145A4 (en) * | 2014-05-16 | 2017-12-27 | Yale University | Evolution of high-titer virus-like vesicles for vaccine applications |
WO2016048949A1 (en) | 2014-09-22 | 2016-03-31 | Regents Of The University Of Minnesota | Pichinde virus reverse genetics system and methods of use |
GB201603374D0 (en) | 2016-02-26 | 2016-04-13 | Ucl Business Plc | Packaging cell |
CN107190022B (zh) * | 2017-06-28 | 2020-10-30 | 浙江大学 | 一种快速构建禽传染性支气管炎病毒反向遗传株的方法 |
US11254953B2 (en) * | 2018-04-18 | 2022-02-22 | Utah State University | Compositions and methods for zika virus characterization and vaccine development |
KR102119875B1 (ko) * | 2019-03-19 | 2020-06-05 | 한국화학연구원 | 한국형 중동호흡기증후군 코로나바이러스 감염성 변이 유전자 및 이의 용도 |
CN110468113A (zh) * | 2019-08-07 | 2019-11-19 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 重组修饰的猪传染性胃肠炎病毒强毒株及其应用 |
CN110656120A (zh) * | 2019-10-16 | 2020-01-07 | 中国医学科学院医学生物学研究所 | 一种乙脑病毒sa14-14-2的克隆方法及应用 |
CN111662885A (zh) * | 2020-06-22 | 2020-09-15 | 扬州大学 | 两株基因组高度同源猪繁殖与呼吸综合征病毒强弱毒株感染性克隆构建、拯救与应用 |
CN112852873B (zh) * | 2021-02-04 | 2023-03-24 | 华中农业大学 | 一种猪δ冠状病毒感染性克隆质粒的构建方法 |
CN115094142B (zh) * | 2022-07-19 | 2024-05-28 | 中国医学科学院肿瘤医院 | 用于诊断肺肠型腺癌的甲基化标志物 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
US5545412A (en) * | 1985-01-07 | 1996-08-13 | Syntex (U.S.A.) Inc. | N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5106733A (en) * | 1987-06-25 | 1992-04-21 | Immunex Corporation | Bovine granulocyte-macrophage colony stimulating factor |
JPH04503306A (ja) | 1989-02-01 | 1992-06-18 | ザ・ジェネラル・ホスピタル・コーポレーション | 単純ヘルペスウイルス1型発現ベクター |
US5811103A (en) * | 1989-03-19 | 1998-09-22 | Akzo Nobel N.V. | Hog cholera virus vaccine and diagnostic |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
CA2039921A1 (en) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
ES2026827A6 (es) * | 1991-03-26 | 1992-05-01 | Ercros Sa | Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino. |
US6033904A (en) * | 1992-01-13 | 2000-03-07 | Syntro Corporation | Recombinant swinepox virus |
US5382425A (en) * | 1992-01-13 | 1995-01-17 | Syntro Corporation | Recombinant swinepox virus |
US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
DE69426228T2 (de) * | 1993-02-08 | 2001-03-01 | Bayer Ag | Verfahren zum Vermehren des das Reproduktions- und Atemwegs-Syndrom verursachenden Schweinevirus und dessen Verwendung als Impfstoff. |
WO1994029469A2 (en) * | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmids suitable for gene therapy |
US20020146392A1 (en) | 1993-06-24 | 2002-10-10 | Frank L. Graham | Helper dependent adenovirus vectors based on site-specific recombinases |
WO1995003400A1 (en) | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
WO1995024929A2 (en) * | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
AU694519B2 (en) * | 1994-04-29 | 1998-07-23 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
DK53595A (da) * | 1994-05-13 | 1995-11-14 | Iberica Cyanamid | Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
WO1996015779A1 (en) | 1994-11-21 | 1996-05-30 | The Trustees Of Columbia University In The City Of New York | Unique associated kaposi's sarcoma virus sequences and uses thereof |
US5719131A (en) * | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
ES2264136T3 (es) | 1995-02-21 | 2006-12-16 | Cantab Pharmaceuticals Research Limited | Preparaciones virales, vectores, inmunogenos y sus vacunas. |
US6043232A (en) * | 1997-07-23 | 2000-03-28 | Nitromed, Inc. | Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs |
US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5820869A (en) * | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US5851826A (en) | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
US5795872A (en) * | 1995-09-19 | 1998-08-18 | Pharmadigm, Inc. | DNA construct for immunization |
US6133243A (en) | 1996-02-22 | 2000-10-17 | Onyx Pharmaceuticals, Inc. | Liposomal-viral DNA complexes for treating disease |
ES2109189B1 (es) | 1996-03-14 | 1998-05-16 | Iberica Cyanamid | Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas. |
FR2751224B1 (fr) * | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
US6004777A (en) * | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
DE19733364A1 (de) * | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
US7211379B2 (en) * | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
US6391314B1 (en) * | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
FR2781159B1 (fr) * | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
UA78180C2 (uk) * | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
US6517843B1 (en) * | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
US6165493A (en) * | 1997-10-22 | 2000-12-26 | New York Blood Center, Inc. | "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections" |
US20040062775A1 (en) * | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
FR2772047B1 (fr) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
JP3795751B2 (ja) * | 1997-12-11 | 2006-07-12 | ユニバーシティ オブ サスカッチェワン | ブタからの離乳後多全身系消耗症候群ウイルス |
US6277621B1 (en) * | 1998-02-26 | 2001-08-21 | Medigene, Inc. | Artificial chromosome constructs containing foreign nucleic acid sequences |
WO1999045956A1 (en) * | 1998-03-13 | 1999-09-16 | University Of Georgia Research Foundation, Inc. | Vaccines against circovirus infections |
US6497883B1 (en) * | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
ES2170622B1 (es) | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
ATE458062T1 (de) | 1999-12-14 | 2010-03-15 | Novartis Pharma Gmbh | Auf bovinem immundefizienvirus (biv) basierende vektoren |
WO2001090340A2 (en) | 2000-05-21 | 2001-11-29 | University Of North Carolina At Chapel Hill | Assembly of large viral genomes and chromosomes from subclones |
DE10044648A1 (de) * | 2000-09-08 | 2002-03-21 | Aventis Behring Gmbh | Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material |
WO2002077210A2 (en) * | 2001-03-27 | 2002-10-03 | University Of Saskatchewan | Methods to culture circovirus |
-
1999
- 1999-12-03 ES ES009902673A patent/ES2170622B1/es not_active Expired - Fee Related
-
2000
- 2000-11-30 IL IL14985900A patent/IL149859A0/xx unknown
- 2000-11-30 CA CA002393325A patent/CA2393325A1/en not_active Abandoned
- 2000-11-30 TR TR2004/01186T patent/TR200401186T4/tr unknown
- 2000-11-30 RS YUP-375/02A patent/RS50372B/sr unknown
- 2000-11-30 EP EP04007406A patent/EP1437400A3/en not_active Withdrawn
- 2000-11-30 KR KR1020027007118A patent/KR100755814B1/ko not_active IP Right Cessation
- 2000-11-30 HU HU0203305A patent/HU228205B1/hu not_active IP Right Cessation
- 2000-11-30 MX MXPA02005525A patent/MXPA02005525A/es active IP Right Grant
- 2000-11-30 PT PT00990628T patent/PT1234024E/pt unknown
- 2000-11-30 EP EP00990628A patent/EP1234024B2/en not_active Expired - Lifetime
- 2000-11-30 CZ CZ20021882A patent/CZ302785B6/cs not_active IP Right Cessation
- 2000-11-30 SI SI200030394T patent/SI1234024T2/sl unknown
- 2000-11-30 CN CNB008165904A patent/CN100402643C/zh not_active Expired - Fee Related
- 2000-11-30 US US10/148,669 patent/US7445928B2/en not_active Expired - Fee Related
- 2000-11-30 BR BR0016145-4A patent/BR0016145A/pt not_active IP Right Cessation
- 2000-11-30 AT AT00990628T patent/ATE267246T1/de active
- 2000-11-30 PL PL356390A patent/PL206816B1/pl not_active IP Right Cessation
- 2000-11-30 DE DE60010921T patent/DE60010921T3/de not_active Expired - Lifetime
- 2000-11-30 CN CNA2006100733455A patent/CN1872994A/zh active Pending
- 2000-11-30 DK DK00990628.0T patent/DK1234024T4/da active
- 2000-11-30 CN CNA2004100789786A patent/CN1616670A/zh active Pending
- 2000-11-30 AU AU30051/01A patent/AU785081B2/en not_active Ceased
- 2000-11-30 ES ES00990628T patent/ES2218276T5/es not_active Expired - Lifetime
- 2000-11-30 WO PCT/EP2000/012063 patent/WO2001039797A2/en active IP Right Grant
- 2000-11-30 SK SK761-2002A patent/SK7612002A3/sk unknown
- 2000-11-30 JP JP2001541529A patent/JP4637432B2/ja not_active Expired - Fee Related
- 2000-11-30 NZ NZ518990A patent/NZ518990A/en not_active IP Right Cessation
- 2000-12-04 AR ARP000106406A patent/AR027893A1/es active IP Right Grant
-
2002
- 2002-05-06 ZA ZA200203560A patent/ZA200203560B/xx unknown
- 2002-05-22 NO NO20022419A patent/NO331812B1/no not_active IP Right Cessation
- 2002-05-27 IL IL149859A patent/IL149859A/en not_active IP Right Cessation
- 2002-09-11 US US10/238,786 patent/US7368557B2/en not_active Expired - Fee Related
-
2006
- 2006-08-03 AU AU2006203327A patent/AU2006203327B2/en not_active Ceased
-
2008
- 2008-09-30 US US12/285,213 patent/US20100167352A1/en not_active Abandoned
-
2010
- 2010-11-03 US US12/938,771 patent/US20110142879A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200401186T4 (tr) | Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları. | |
Ishida et al. | Polymorphic sequence in the D‐loop region of equine mitochondrial DNA | |
Cornelissen et al. | Complete nucleotide sequence of tobacco streak virus RNA 3 | |
WO1999020766A3 (en) | NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS | |
CA2196555A1 (en) | Vr-2332 viral nucleotide sequence and methods of use | |
EP0331939A3 (en) | Method and compositions for conferring resistance to retroviral infection | |
ATE466948T1 (de) | Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle | |
JP2002537791A5 (tr) | ||
CY1106216T1 (el) | 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ | |
CY1106806T1 (el) | Dna και πολυπεπτιδια ανθρωπινης tslp | |
FI875082A0 (fi) | Dna-sekvensser deriverade fraon genom av papillomavirus, deras anvaendning foer in vitro diagnostiska aendamaol; samt framstaellning av antigeniska kompositioner. | |
ATE335086T1 (de) | Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten | |
WO1998046788A3 (en) | Primers and methods for the detection of disseminated tumor cells | |
BR9915969A (pt) | Toxinas pesticidas e seq ências de nucleotìdeos que codificam estas toxinas | |
ATE412736T1 (de) | Retrovirus aus der hiv-gruppe und dessen verwendung | |
Kreivi et al. | Sequences involved in the control of adenovirus L1 alternative RNA splicing | |
TR200003272T2 (tr) | Protein üretimi verilmesi için G-CSF geninin genomik sekanslar. | |
ATE211180T1 (de) | Verfahren zur nicht-radioaktiven detektion von membran-gebundenen nukleinsäuren und testkit | |
AU686000B2 (en) | Infectious peritonitis vaccine | |
DE60229966D1 (de) | Diabetesmodell | |
Janda et al. | Preparation and sequencing of the cloacin fragment of Streptomycesaureofaciens 16S RNA | |
NZ512308A (en) | Chlamydia antigens and corresponding DNA fragments and uses thereof | |
WO2003054181A3 (en) | Nucleic acid labeling by thermoanaerobacter thermohydrosulfuricus dna polymerase i variants | |
WO2004003009A3 (en) | Francisella tularensis immunogenic proteins and dna encoding these | |
DE69925927D1 (de) | Mutmassliches 98 kd protein des aussenmembrans von chlamydia und dafür kodierende dns sowie deren verwendung |